Clinical trial
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer…
NCT00049257 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00049257 |
|---|---|
| Title | Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Hormone-Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel |
| Enrollment | 58 |
| Start date | Oct 1, 2002 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 1, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: